Your Conference Booth Is an Ad. The FDA May Treat It Like One.
Pharma conference marketing often feels different from traditional advertising. A booth sits inside a scientific meeting, conversations happen among healthcare professionals, and clinical data...
Only 14% of Women Knew This Was a Menopause Symptom. That’s the Opportunity.
Women’s health marketing has an important challenge: patients cannot ask about a health connection they do not know exists. A new Bausch + Lomb...
Bimzelx Spent $31 Million on TV. What Is UCB Buying?
UCB just made one of the most striking moves in pharma TV ad spending this year. Bimzelx jumped from roughly $5.5 million in estimated...
What Happens to Pharma TV Advertising If the Fine Print Can’t Live Somewhere Else?
Pharma TV advertising has long depended on a practical compromise: explain the most important risks on screen, then direct viewers elsewhere for fuller prescribing...
Snapchat Just Made Pharma Ads Easier to Run. Will Brand Teams Actually Use It?
Pharma advertising on Snapchat has always faced a basic problem: social media moves fast, while prescription drug advertising carries extensive disclosure requirements. Snapchat is...
Before the $1 Million Shoot: Can “Faux Pharma” Make Real Campaigns Better?
Before a pharma brand commits to a major commercial shoot, what if it could test a convincing version of the campaign first? Synthetic ad...
The Asthma Dinosaur and the Psoriasis Weed: Why Pharma Ads Are Getting Weirder and...
Pharmaceutical advertising used to have a familiar visual language: smiling patients, sunny kitchens, walks in the park, and reassuring conversations with doctors. Now, a...
The “Pharma-as-a-Pharmacy” Pivot: Why Direct-to-Patient Models Are Rewriting Commercial Strategy
Direct-to-patient pharma is evolving from an access experiment into a broader commercial strategy. Manufacturer-led platforms such as LillyDirect and PfizerForAll are creating more connected...
Pharma Measurement Has a New Problem: Too Many “Correct” Answers
Pharma marketers once struggled to get enough performance data. Today, the problem is almost the opposite. DSPs, publishers, clean rooms, audience platforms, agencies, and...
One Commercial Leader, Fewer Silos: Daiichi Sankyo’s Reorg Raises a Bigger Marketing Question
What happens when a pharmaceutical company puts more of its commercial engine under one leader? Daiichi Sankyo is about to provide a useful case...
